The Campaign to Stop Colon Cancer Now, a campaign to increase screenings and prevent the nation's second-leading cancer killer, launched today in conjunction with National Colorectal Cancer Awareness Month in March.

Patients with irritable bowel syndrome are at no greater risk of having polyps, colon cancer or inflammatory bowel diseases than healthy people undergoing colonoscopies, according to new research published in the American Journal of Gastroenterology.

Obese patients with colon cancer are at greater risk for death or recurrent disease compared to those who are within a normal weight range, according to a report in Clinical Cancer Research, a journal of the American Association for Cancer Research.

Viatronix Incorporated, a Stony Brook, New York, based company announced that its V3D-Colon software is used at the National Naval Medical Center where the President's annual physical was done. "Our software is being utilized at several DOD facilities since the landmark Virtual Colonoscopy clinical trial published in the New England Journal of Medicine back in December 2003," said Zaffar Hayat, President of Viatronix Incorporated.

A new national survey reveals that while almost all Canadians understand the importance of getting checked for colon cancer, most have not had a screening test and are confused about how and when it should happen.

Christopher Fey, Chairman and CEO of U.S. Preventive Medicine®, today announced the company's groundbreaking approach to prevention was featured on "Hannity" on FOX News Channel.

Major League Baseball slugger Aaron Boone will be featured on January's episode of Sharing Miracles - a 30-minute public affairs television program that tells the compelling and inspirational stories of real patients. Sharing Miracles airs every week on more than 300 television stations nationwide.

People carrying the germ-line MSH6 mutation are at high risk by age 80 years for colorectal and endometrial cancers and any cancer associated with Lynch syndrome, according to a new study published online December 22 in the Journal of the National Cancer Institute.

Genomic Health, Inc. today announced results from a study demonstrating the critical role of manual microdissection to remove all biopsy cavities from breast cancer specimens. Genomic Health's Oncotype DX is the only commercially available breast cancer test that employs manual microdissection following review by a board certified surgical pathologist with breast expertise to predict a patient's benefit from chemotherapy and risk of disease recurrence.